Akoya Biosciences And Thermo Fisher Scientific Announced Earlier Sunday, A License And Distribution Agreement To Deliver Spatial Multiomics Workflow
Portfolio Pulse from Charles Gross
Akoya Biosciences, Inc. (AKYA) has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. (TMO) to market a spatial multiomics workflow. This collaboration combines Akoya's PhenoImager systems and PhenoCode reagents with Thermo Fisher's ViewRNA In Situ Hybridization Assays. The partnership aims to provide a comprehensive suite of multiomic solutions to enhance the understanding of tumor progression and biomarker development.
January 07, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akoya Biosciences' agreement with Thermo Fisher to market spatial multiomics solutions could enhance its product offerings and market reach, potentially leading to increased revenue and market share.
The agreement with Thermo Fisher is likely to have a positive impact on Akoya Biosciences' short-term stock performance. The partnership could expand Akoya's market reach and enhance its product portfolio, which may be viewed favorably by investors.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Thermo Fisher's collaboration with Akoya Biosciences to integrate its ViewRNA assays into Akoya's spatial biology solutions may strengthen its position in the multiomics field and could lead to incremental revenue growth.
Thermo Fisher's partnership with Akoya is expected to have a positive impact on its stock in the short term. The integration of its assays with Akoya's systems may be seen as a strategic move to capture more of the multiomics market, which could lead to positive investor sentiment.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 60